Basically Kane told you. Setip. will not be a miracle drug. If you want to assess its postential, you can use OC now. However, if Setip. cannot be used locally it will likely perform worse than OC. Also keep in mind that PGD2 is downstream of 5-ar and AR, so, if you already use 5-ar inhibitors or androgen receptor antagonists or (preferably) both concurrently, PGD2 antagonists may have no (or no big) additional effect. But possibly one can substitute PGD2 antagonists for 5-ar/AR inhibitors/antagonists, if it makes sense that is, if there's less (less severe) systemic side effects. Or at least that Setip. will be cheaper than OC, but I doubt that Kythera will sell it for cheap, if they bring it to market anyway.